This Month's GLP-1 Price Check: Where the Best Deals Landed (March 2026)

Keeping up with GLP-1 prices is genuinely exhausting — they shift month to month, and every program frames its pricing a little differently. So each month we track what the six programs we cover are charging and translate it into a clear snapshot. Consider this your shortcut to the current deals.

Below you'll find who's cheapest right now, how the headline starter prices compare to ongoing maintenance cost, and the trade-offs behind each option. We'll always flag where a low front-page price comes with a catch, because the cheapest number isn't always the best choice for you.

Embody had the lowest entry price at $99 for the first month — but read the fine print with us. That's compounded semaglutide at an introductory rate, and the ongoing cost climbs to roughly $299/month after that first month. So the true cost over time is meaningfully higher than the headline. (If needles aren't your thing, Embody also offers a GLP-1 gum from $199/mo.)

For the lowest ongoing price, Yucca Health was the standout at $129/month for compounded semaglutide, with no membership fee — and it's our Editor's Pick. Bodybuilding Health+ followed close behind from $139/month on a 12-month bundle. If you'd rather skip the needle or want brand-name options on the table, ShedRx (from $195/mo, with needle-free drops, lozenges, and the FDA-approved Foundayo pill) and MEDVi ($179 first month, then ~$299/mo, with unlimited visits included) each serve a different priority — lowest price, needle-free choice, or full-service support.

The single most useful thing to notice this month is the gap between a program's first-month price and its maintenance price. Embody's $99 intro is the cheapest way to get started, but at $129/month every month, Yucca Health is the cheaper choice once you're settled into a maintenance dose. MEDVi's $179 first month is a gentle on-ramp, then it steps up to around $299/month.

These differences are exactly why we recheck monthly and why we always quote both numbers. A program with the lowest starter price isn't automatically the cheapest over six months. If you're shopping, do a quick six-month projection at your expected maintenance dose rather than relying on the front-page teaser.

Here's an encouraging trend: the price gap between compounded and brand-name GLP-1s is closing as savings programs and insurance coverage expand. Around a year ago, compounded semaglutide ran $150–200 versus $300–500 for brand-name Wegovy — a wide chasm. That gap is shrinking.

That matters because it changes the calculus. As FDA-approved options get cheaper, the savings from going compounded shrink, while the supply risk remains — underscored by the 12 FDA warning letters issued this month. For many people, a slightly higher price for FDA approval is starting to look like the better deal.

Not all the news is about cuts — commercial coverage is expanding in places too. Notably, UnitedHealthcare, the largest US insurer, confirmed in February that it will maintain GLP-1 coverage for obesity (BMI 30+) across all its plans in 2026.

That's a meaningful counterweight to the coverage losses elsewhere. If you're a UnitedHealthcare member, it's worth confirming your specific plan's terms, because covered access is almost always cheaper than any cash-pay route.

The big picture in March 2026 is that the market is getting more affordable. Our guidance: prioritize FDA-approved medications where you can, since the price gap to compounded is narrowing and the supply risk on compounded is real.

If you're currently on a compounded plan, this is a good month to start planning a transition before supply tightens. And whatever you choose, confirm the current rate and the maintenance-dose price — not just the headline starter number — before you commit.